Literature DB >> 21571732

Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement.

Mirko Manetti, Serena Guiducci, Claudia Ceccarelli, Eloisa Romano, Silvia Bellando-Randone, Maria Letizia Conforti, Lidia Ibba-Manneschi, Marco Matucci-Cerinic.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571732     DOI: 10.1136/ard.2010.148247

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  17 in total

1.  Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels.

Authors:  Serena Vettori; Giovanna Cuomo; Michele Iudici; Virginia D'Abrosca; Veronica Giacco; Giusi Barra; Raffaele De Palma; Gabriele Valentini
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

2.  Serum IL-33 level and IL-33 gene polymorphisms in Behçet's disease.

Authors:  Suleyman Serdar Koca; Murat Kara; Firat Deniz; Metin Ozgen; Caner Feyzi Demir; Nevin Ilhan; Ahmet Isik
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

3.  Association of interleukin 1 family with systemic sclerosis.

Authors:  Li Zhang; Jun-Wei Yan; Yu-Jie Wang; Ya-Nan Wan; Bing-Xiang Wang; Jin-Hui Tao; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

4.  Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis: an independent case-control study and a meta-analysis.

Authors:  Xiao-Lei Huang; Guo-Cui Wu; Yu-Jie Wang; Xiao-Ke Yang; Guo-Jun Yang; Jin-Hui Tao; Yu Duan; Jun-Wei Yan; Xiang-Pei Li; Dong-Qing Ye; Jing Wang
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

5.  Elevated serum levels of interleukin-1β and interleukin-33 in patients with systemic sclerosis in Chinese population.

Authors:  Y-J Zhang; Q Zhang; G-J Yang; J-H Tao; G-C Wu; X-L Huang; Y Duan; X-P Li; D-Q Ye; J Wang
Journal:  Z Rheumatol       Date:  2018-03       Impact factor: 1.372

6.  Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement.

Authors:  Francesco Iannazzo; Chiara Pellicano; Amalia Colalillo; Cesarina Ramaccini; Antonella Romaniello; Antonietta Gigante; Edoardo Rosato
Journal:  Clin Exp Med       Date:  2022-07-25       Impact factor: 5.057

7.  The IL-33 gene is related to increased susceptibility to systemic sclerosis.

Authors:  Suleyman Serdar Koca; Yavuz Pehlivan; Murat Kara; Fatma Alibaz-Oner; Serdar Oztuzcu; Neslihan Yilmaz; Gozde Yildirim Cetin; Bunyamin Kisacik; Metin Ozgen; Omer Nuri Pamuk; Haner Direskeneli; Mehmet Sayarlioglu; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2016-01-07       Impact factor: 2.631

Review 8.  The immune pathogenesis of scleroderma: context is everything.

Authors:  Matthew B Greenblatt; Antonios O Aliprantis
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

Review 9.  The role of IL-33 in rheumatic diseases.

Authors:  Lihua Duan; Jie Chen; Feili Gong; Guixiu Shi
Journal:  Clin Dev Immunol       Date:  2013-09-15

Review 10.  Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis.

Authors:  Liya Li; Honglin Zhu; Xiaoxia Zuo
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.